You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Double-hit lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Double Hit Lymphoma, Triple Hit Lymphoma Trial in Hangzhou (Selinexor+RCHOP)

Recruiting
  • Double Hit Lymphoma
  • Triple Hit Lymphoma
  • Hangzhou, Zhenjiang, China
    Zhejiang Cancer Hospital
Aug 2, 2023

Multiple Myeloma (MM), DLBCL, Not Otherwise Specified, Double Hit Lymphoma Trial in Spain (IDP-121)

Recruiting
  • Multiple Myeloma (MM)
  • +5 more
  • Santander, Cantabria, Spain
  • +4 more
Jun 19, 2023

Lymphoma, Large B-Cell, Diffuse, Mantle Cell Lymphoma, Peripheral T Cell Lymphoma Trial in Nanjing (Chidamide)

Active, not recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • +3 more
  • Nanjing, Jiangsu, China
    Hematological Department, People's Hospital of Jiangsu Province
Dec 30, 2021

Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

Not yet recruiting
  • Refractory Aggressive B-cell Lymphomas
  • +12 more
  • Boston, Massachusetts
  • +1 more
Oct 13, 2022

High-grade B-cell Lymphoma, Burkitt Lymphoma, Lymphoma, B-Cell Trial in Busan, Seoul (Sepantronium Bromide)

Not yet recruiting
  • High-grade B-cell Lymphoma
  • +8 more
  • Sepantronium Bromide
  • Busan, Korea, Republic of
  • +5 more
Feb 27, 2022

Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia Trial in Houston

Recruiting
  • Recurrent Acute Lymphoblastic Leukemia
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 21, 2022

DLBCL, High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • +2 more
  • Tampa, Florida
  • +1 more
Jan 12, 2022

Lymphoma, Relapsed Lymphoma, Refractory Lymphoma Trial in United States (fimepinostat, Rituximab, venetoclax)

Completed
  • Lymphoma
  • +10 more
  • Los Angeles, California
  • +10 more
May 5, 2021

Malignant Lymphoma, Multiple Myeloma Trial (Pentaisomaltose)

Not yet recruiting
  • Malignant Lymphoma
  • Multiple Myeloma
  • Pentaisomaltose
  • (no location specified)
Jan 5, 2023

Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma

Not yet recruiting
  • Double-Expressor Lymphoma
  • +3 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Oct 27, 2022

The First Affiliated Hospital of Nanchang University Trial in Nanchang, Jinan (Orelabrutinib+R-CHOP)

Recruiting
  • The First Affiliated Hospital of Nanchang University
  • Nanchang, Jiangxi, China
  • +1 more
Jul 3, 2023

T-cell Lymphoma Patients After First-line Treatment Failure Trial (SHR2554; Chidamide analog tablets, SHR2554 analog tablets;

Not yet recruiting
  • T-cell Lymphoma Patients After First-line Treatment Failure
  • SHR2554; Chidamide analog tablets
  • SHR2554 analog tablets; Chidamide
  • (no location specified)
Nov 5, 2023

Extranodal NK/T-cell Lymphoma Trial (Sugemalimab, Placebo, Pegaspargase)

Not yet recruiting
  • Extranodal NK/T-cell Lymphoma
  • Sugemalimab
  • +4 more
  • (no location specified)
Jan 17, 2023

Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL) Trial (parsaclisib, rituximab, obinutuzumab)

Withdrawn
  • Follicular Lymphoma ( FL)
  • Marginal Zone Lymphoma (MZL)
  • (no location specified)
Jul 14, 2022

Relapsed/Refractory Marginal Zone Lymphoma Trial in China (Orelabrutinib, Lenalidomide, Rituximab)

Not yet recruiting
  • Relapsed/Refractory Marginal Zone Lymphoma
  • Guangzhou, Guangdong, China
  • +10 more
Oct 8, 2023

Non Hodgkin Lymphoma, Lymphoma, B-Cell, High-grade B-cell Lymphoma Trial in Belgium, Netherlands (DA-EPOCH-R followed by

Active, not recruiting
  • Non Hodgkin Lymphoma
  • +4 more
  • DA-EPOCH-R followed by Nivolumab
  • Antwerpen, Belgium
  • +23 more
Mar 23, 2022

Lymphoma, Mantle-Cell, Lymphoma, Lymphoproliferative Disorders Trial (Zilovertamab, Ibrutinib, Placebo)

Not yet recruiting
  • Lymphoma, Mantle-Cell
  • +7 more
  • (no location specified)
Jun 21, 2022

Predict CNS Involvement in Diffuse Large B-Cell Lymphoma:Danish

Completed
  • Diffuse Large B Cell Lymphoma
  • +2 more
    • (no location specified)
    Dec 13, 2021

    Mantle Cell Lymphoma Trial (parsaclisib, rituximab, bendamustine)

    Withdrawn
    • Mantle Cell Lymphoma
    • (no location specified)
    Apr 22, 2022

    Diffuse Large B Cell Lymphoma (DLBCL) Trial in Shanghai (Orelabrutinib + R-CHOP, Placebo + R-CHOP)

    Recruiting
    • Diffuse Large B Cell Lymphoma (DLBCL)
    • Orelabrutinib + R-CHOP
    • Placebo + R-CHOP
    • Shanghai, Shanghai, China
      Shanghai Ruijing Hospital
    Nov 28, 2022

    Classic Hodgkin's Lymphoma Trial in Beijing (Sintilimab, Carboplatin, Etoposide)

    Recruiting
    • Classic Hodgkin's Lymphoma
    • Sintilimab
    • +4 more
    • Beijing, Beijing, China
      Cancer Hospital Chinese Academy of Medical Sciences
    Sep 12, 2022

    Diffuse Large B-cell Lymphoma(DLBCL) Trial in Shanghai (Zanubrutinib + R-CHOP)

    Recruiting
    • Diffuse Large B-cell Lymphoma(DLBCL)
    • Zanubrutinib + R-CHOP
    • Shanghai, China
      Fudan University Shanghai Cancer Center
    Feb 10, 2022

    Diffuse Large B Cell Lymphoma Trial (Epcoritamab, Lenalidomide)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma
    • (no location specified)
    Jan 20, 2023

    Brain Concussion Trial in Philadelphia (Branched Chain Amino Acids, Placebo solution)

    Recruiting
    • Brain Concussion
    • Branched Chain Amino Acids
    • Placebo solution
    • Philadelphia, Pennsylvania
      The Children's Hospital of Philadelphia
    Mar 22, 2022

    DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to DLBCL Trial

    Not yet recruiting
    • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
    • +2 more
    • Biospecimen Collection
    • +5 more
    • (no location specified)
    Sep 5, 2023